Abstract:BackgroundMR imaging has been applied to determine therapeutic response to glucocorticoid (GC) before treatment in thyroid‐associated ophthalmopathy (TAO), while the performance was still poor.PurposeTo investigate the value of T2‐weighted imaging (T2WI)‐derived radiomics for pretreatment determination of therapeutic response to GC in TAO patients, and compare its diagnostic performance with that of semiquantitative parameters.Study TypeRetrospective.PopulationA total of 110 patients (49 ± 12 years; male/female, n = 48/62; responsive/unresponsive, n = 62/48), divided into training (n = 78) and validation (n = 32) cohorts.Field Strength/Sequence3.0 T, T2‐weighted fast spin echo.AssessmentW.C. and H.H. (6 and 10 years of experience, respectively) performed the measurements. Maximum, mean, and minimum signal intensity ratios (SIRs) of extraocular muscle (EOM) bellies were collected to construct a semiquantitative imaging model. Radiomics features from volumes of interest covering EOM bellies were extracted and three machine learning‐based (logistic regression [LR]; decision tree [DT]; support vector machine [SVM]) models were built.Statistical TestsThe diagnostic performances of models were evaluated using receiver operating characteristic curve analyses, and compared using DeLong test. Two‐sided P < 0.05 was considered statistically significant.ResultsThe responsive group showed higher minimum signal intensity ratio (SIRmin) of EOMs than the unresponsive group (training: 1.46 ± 0.34 vs. 1.18 ± 0.39; validation: 1.44 ± 0.33 vs. 1.19 ± 0.20). In both cohorts, LR‐based radiomics model demonstrated good diagnostic performance (area under the curve [AUC] = 0.968, 0.916), followed by DT‐based (AUC = 0.933, 0.857) and SVM‐based models (AUC = 0.919, 0.855). All three radiomics models outperformed semiquantitative imaging model (SIRmin: AUC = 0.805) in training cohort. In validation cohort, only LR‐based radiomics model outperformed that of SIRmin (AUC = 0.745). The nomogram integrating LR‐based radiomics signature and disease duration further elevated the diagnostic performance in validation cohort (AUC: 0.952 vs. 0.916, P = 0.063).Data ConclusionT2WI‐derived radiomics of EOMs, together with disease duration, provides a promising noninvasive approach for determining therapeutic response before GC administration in TAO patients.Level of Evidence3Technical EfficacyStage 4

Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL

T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy

T2 Mapping Histogram at Extraocular Muscles for Predicting the Response to Glucocorticoid Therapy in Patients with Thyroid-Associated Ophthalmopathy.

Determining Disease Activity and Glucocorticoid Response in Thyroid-Associated Ophthalmopathy: Preliminary Study Using Dynamic Contrast-Enhanced MRI

Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy

T2‐Weighted MR Imaging‐Derived Radiomics for Pretreatment Determination of Therapeutic Response to Glucocorticoid in Patients with Thyroid‐Associated Ophthalmopathy: Comparison with Semiquantitative Evaluation

Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?

T Cell Subsets Are Associated with Clinical Activity and Efficacy of 4.5g Intravenous Glucocorticoid for Moderate-To-Severe Thyroid-Associated Ophthalmopathy.

Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues

A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy

Three Dimensional Orbital Magnetic Resonance T2-mapping in the Evaluation of Patients with Graves’ Ophthalmopathy

A Novel Nomogram to Predict Glucocorticoid Response in Thyroid-Associated Ophthalmopathy: Findings from a Pilot Study

ROLE OF MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF ACTIVE THYROID-ASSOCIATED OPHTHALMOPATHY PATIENTS WITH LONG DISEASE DURATION.

Factors Associated with the Efficacy of Intravenous Methylprednisolone in Moderate-to-severe and Active Thyroid-Associated Ophthalmopathy: A Single-Centre Retrospective Study.

T2 Relaxation Time in Extraocular Muscles of Patients with Mild Thyroid- Associated Ophthalmopathy: Comparing T2 Mapping With and Without Fat Suppression Using Different Measurement Methods

Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and orbital MRI parameter

Radiological Staging of Thyroid-Associated Ophthalmopathy: Comparison of T1 Mapping with Conventional MRI

Predicting Glucocorticoid Effectiveness in Thyroid Eye Disease: Combined Value from Serological Lipid Metabolism and an Orbital MRI Parameter.

Influence of 4‐week or 12‐week Glucocorticoid Treatment on Metabolic Changes in Patients with Active Moderate‐to‐severe Thyroid‐associated Ophthalmopathy

Thyroid-Associated Ophthalmopathy: Preliminary Study Using T2 Mapping to Characterize Intraorbital Optic Nerve Changes Before Dysthyroid Optic Neuropathy.

The Efficacy of Intensity Modulated Radiation Therapy in Treating Thyroid-Associated Ophthalmopathy and Predictive Factors for Treatment Response